Explore Business Standard
Don’t miss the latest developments in business and finance.
Drug major Aurobindo Pharma on Wednesday said its wholly-owned subsidiary has received approval from the US health regulator to market anti-cancer medication Bortezomib for injection. Eugia Pharma Specialties has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market the product, a generic equivalent of Takeda Pharmaceuticals' Velcade for injection, the Hyderabad-based company said in a statement. The product, which is indicated for the treatment of multiple myeloma (cancer of plasma cells) and mantle cell lymphoma (cancer of lymph nodes), is being launched immediately, it added. According to IQVIA, the approved product has a market size of USD 1,172 million for the twelve months ending March 2022.
Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures. The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing. Indoco Remedies Managing Director Aditi Kare Panandikar said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide tablets has already reached the US". Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug, the company said. Citing IQVIA sales data for the period ending January 2022, the company ..
Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults. The request is broader than rival pharmaceutical company Pfizer's request earlier this week for the regulator to approve a booster shot for all seniors. In a press release, the company said its request for approval for all adults was made to provide flexibility to the Centers for Disease Control and Prevention and medical providers to determine the appropriate use of a second booster dose of the mRNA vaccine, including for those at higher risk of COVID-19 due to age or comorbidities." U.S. officials have been laying the groundwork to deliver additional booster doses to shore up the vaccines' protection against serious disease and death from COVID-19. The White House has been sounding the alarm that it needs Congress to urgently approve more funding for the federal government to secure more doses of the COVID-19 vaccines, either fo
Cadila Healthcare on Friday said its US arm Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market generic Pimavanserin capsules, indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said. The group now has 325 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.
The US Food and Drug Administration (FDA) on Wednesday (local time) authorized Pfizer's Paxlovid COVID-19 pill for high-risk people aged 12 and over to treat coronavirus disease (COVID-19)."The US Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer's Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death," US Food and Drug said in a statement."Today's authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally -- a major step forward in the fight against this global pandemic," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and